文献速递呼吸衰竭与机械通气儿科与产科急症

2019年全球早产婴幼儿呼吸道合胞病毒相关急性下呼吸道感染的疾病负担与危险因素:聚合数据与个体参与者数据的系统评价和Meta分析

Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data.
PubMed 文献 · Lancet · 2024-02-14
一句话结论2019年全球早产儿RSV相关ALRI住院占所有婴幼儿RSV住院的25%,早产儿(尤其<32周)住院负担持续至生后第二年。

该系统评价与Meta分析纳入47项文献研究和17项个体参与者数据研究,估计2019年全球早产儿中RSV相关ALRI发病1,650,000例、住院533,000例、院内死亡3,050例、归因死亡26,760例。早产儿占所有胎龄婴幼儿RSV相关ALRI住院的25%。早期早产儿(<32周)住院率显著高于所有胎龄婴幼儿,且持续至生后第二年;晚期早产儿(32至<37周)在生后前6个月住院率亦较高。与严重结局相关的因素主要为基础疾病,包括先天性心脏病、气管切开、支气管肺发育不良、慢性肺病或唐氏综合征(OR 1.40至4.23)。

要点

  • 2019年全球早产儿RSV相关ALRI住院533,000例(95%UR 385,000-730,000),占所有胎龄婴幼儿RSV住院的25%(95%UR 16-37)。
  • 早期早产儿(<32周)RSV相关ALRI发病率和住院率显著高于所有胎龄婴幼儿,不同年龄组和结局的率比(RR)为1.69至3.87。
  • 生后第二年,早期早产儿发病率与所有婴幼儿相似,但住院率仍显著更高(RR 2.26 [95%UR 1.27-3.98])。
  • 晚期早产儿(32至<37周)RSV相关ALRI发病率与所有<1岁婴儿相似,但生后前6个月住院率更高(RR 1.93 [95%UR 1.11-3.26])。
  • 与RSV相关ALRI严重结局相关的因素主要为基础疾病,包括先天性心脏病、气管切开、支气管肺发育不良、慢性肺病或唐氏综合征(OR 1.40至4.23)。

适用人群与场景

  • 胎龄<37周的早产婴幼儿,年龄<2岁。
  • 纳入的研究为1995年1月1日至2021年12月31日发表的文献及呼吸病毒全球流行病学网络共享的个体参与者数据。

研究设计与关键结果

  • 研究类型:系统评价与Meta分析(聚合数据及个体参与者数据),注册号PROSPERO CRD42021269742;纳入47项文献研究和17项个体参与者数据研究。
  • 2019年全球早产儿RSV相关ALRI:发病1,650,000例(95%UR 1,350,000-1,990,000),住院533,000例(385,000-730,000),院内死亡3,050例(1,080-8,620),归因死亡26,760例(11,190-46,240)。
  • 早期早产儿(<32周)RSV相关ALRI发病率和住院率显著高于所有胎龄婴幼儿,不同年龄组和结局的率比(RR)为1.69至3.87。
  • 生后第二年,早期早产儿发病率与所有婴幼儿相似,但住院率仍显著更高(RR 2.26 [95%UR 1.27-3.98])。
  • 晚期早产儿(32至<37周)RSV相关ALRI发病率与所有<1岁婴儿相似,但生后前6个月住院率更高(RR 1.93 [95%UR 1.11-3.26])。
  • 早产儿占所有胎龄婴幼儿RSV相关ALRI住院的25%(95%UR 16-37);早产儿RSV相关ALRI院内病死率与所有婴幼儿相似。
  • 与RSV相关ALRI发病相关的因素主要为围产期和社会人口学特征;与感染严重结局相关的因素主要为基础疾病,包括先天性心脏病、气管切开、支气管肺发育不良、慢性肺病或唐氏综合征(OR 1.40至4.23)。

证据类型、等级与局限

  • 证据类型:系统评价与Meta分析(聚合数据及个体参与者数据)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 早产儿(尤其<32周)RSV相关ALRI住院负担高且持续至生后第二年,临床需关注该人群的RSV预防。
  • 伴有先天性心脏病、气管切开、支气管肺发育不良、慢性肺病或唐氏综合征的早产儿发生RSV相关ALRI严重结局的风险更高(OR 1.40至4.23)。
  • 作者认为,RSV预防产品可通过预防早产儿RSV相关ALRI和感染严重结局产生重大公共卫生影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Infants and young children born prematurely are at high risk of severe acute lower respiratory infection (ALRI) caused by respiratory syncytial virus (RSV). In this study, we aimed to assess the global disease burden of and risk factors for RSV-associated ALRI in infants and young children born before 37 weeks of gestation.

METHODS: We conducted a systematic review and meta-analysis of aggregated data from studies published between Jan 1, 1995, and Dec 31, 2021, identified from MEDLINE, Embase, and Global Health, and individual participant data shared by the Respiratory Virus Global Epidemiology Network on respiratory infectious diseases. We estimated RSV-associated ALRI incidence in community, hospital admission, in-hospital mortality, and overall mortality among children younger than 2 years born prematurely. We conducted two-stage random-effects meta-regression analyses accounting for chronological age groups, gestational age bands (early preterm, <32 weeks gestational age [wGA], and late preterm, 32 to <37 wGA), and changes over 5-year intervals from 2000 to 2019. Using individual participant data, we assessed perinatal, sociodemographic, and household factors, and underlying medical conditions for RSV-associated ALRI incidence, hospital admission, and three severity outcome groups (longer hospital stay [>4 days], use of supplemental oxygen and mechanical ventilation, or intensive care unit admission) by estimating pooled odds ratios (ORs) through a two-stage meta-analysis (multivariate logistic regression and random-effects meta-analysis). This study is registered with PROSPERO, CRD42021269742.

FINDINGS: We included 47 studies from the literature and 17 studies with individual participant-level data contributed by the participating investigators. We estimated that, in 2019, 1 650 000 (95% uncertainty range [UR] 1 350 000-1 990 000) RSV-associated ALRI episodes, 533 000 (385 000-730 000) RSV-associated hospital admissions, 3050 (1080-8620) RSV-associated in-hospital deaths, and 26 760 (11 190-46 240) RSV-attributable deaths occurred in preterm infants worldwide. Among early preterm infants, the RSV-associated ALRI incidence rate and hospitalisation rate were significantly higher (rate ratio [RR] ranging from 1·69 to 3·87 across different age groups and outcomes) than for all infants born at any gestational age. In the second year of life, early preterm infants and young children had a similar incidence rate but still a significantly higher hospitalisation rate (RR 2·26 [95% UR 1·27-3·98]) compared with all infants and young children. Although late preterm infants had RSV-associated ALRI incidence rates similar to that of all infants younger than 1 year, they had higher RSV-associated ALRI hospitalisation rate in the first 6 months (RR 1·93 [1·11-3·26]). Overall, preterm infants accounted for 25% (95% UR 16-37) of RSV-associated ALRI hospitalisations in all infants of any gestational age. RSV-associated ALRI in-hospital case fatality ratio in preterm infants was similar to all infants. The factors identified to be associated with RSV-associated ALRI incidence were mainly perinatal and sociodemographic characteristics, and factors associated with severe outcomes from infection were mainly underlying medical conditions including congenital heart disease, tracheostomy, bronchopulmonary dysplasia, chronic lung disease, or Down syndrome (with ORs ranging from 1·40 to 4·23).

INTERPRETATION: Preterm infants face a disproportionately high burden of RSV-associated disease, accounting for 25% of RSV hospitalisation burden. Early preterm infants have a substantial RSV hospitalisation burden persisting into the second year of life. Preventive products for RSV can have a substantial public health impact by preventing RSV-associated ALRI and severe outcomes from infection in preterm infants.

FUNDING: EU Innovative Medicines Initiative Respiratory Syncytial Virus Consortium in Europe.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Wang X, Li Y, Shi T, et al. Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data. Lancet. 2024. PMID: 38367641. doi:10.1016/S0140-6736(24)00138-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。